tbuckley/cabot-search huggingface dataset:
Abstract 11320: Long-Term Stent-Related and Patient-Related Outcomes of Second-Generation Everolimus-Eluting Xience V Stents versus Zotarolimus-Eluting Resolute Stents in Real-World Practice: Three Year Results From the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries
Authors: Jonghanne Park, Joo Myung Lee, Kyung Woo Park, Jung-Kyu Han, Han-Mo Yang, Hyun-Jae Kang, Bon-Kwon Koo, Jang-Whan Bae, Sung-Il Woo, Jin Sik Park, Dong-Kyu Jin, Dong Woon Jeon, Seok Kyu Oh, Jong-Seon Park, Doo-Il Kim, Min Su Hyon, Hui-Kyung Jeon, Do-Sun Lim, Myeong-Gon Kim, Seung-Woon Rha, Sung-Ho Her, Jin-Yong Hwang, Sanghyun Kim, Young Jin Choi, Jin Ho Kang, Keon-Woong Moon, Yangsoo Jang, Hyo-Soo Kim
Journal: Circulation (2014)

Background: Long term outcomes are imperative to confirm safety of drug-eluting stents. There have been two randomized controlled trials comparing everolimus-eluting stents (EES) and Resolute zotarolimus-eluting stents (ZES-R). To date, long-term clinical outcomes of these stents were limited to only one report which has recently reported 4-year comparisons of these stents. Therefore, more evidences are needed regarding long-term clinical outcomes of the second generation stents. This study compared the long-term clinical outcomes of EES with ZES-R in “all-comer” cohorts up to 3-year follow-up. Methods: The EXCELLENT and RESOLUTE-Korea registries prospectively enrolled 3,056 patients treated with EES and 1,998 with ZES-R. Target lesion failure and patient-related composite events were compared in crude and propensity score matched analyses. Results: Of 5054 patients, 3830 patients (75.8%) had off label indication (2217 with EES and 1613 with ZES-R). The stent-related outcome (189 [6.2%] vs. 127 [6.4%], p=0.812) and the patient-related outcome (420 [13.7%] vs. 250 [12.5%], p=0.581) did not differ between EES and ZES-R respectively at 3 year, which was corroborated by similar results from the propensity score-matched cohort (HR 0.92, 95% CI 0.70-1.20, p=0.523 and 0.85, 95% CI 0.70-1.02, p=0.081, for stent and patient related outcomes, respectively). The rate of definite or probable stent thrombosis up to 3 years (22 [0.7%] vs. 10 [0.5%], p=0.370) was also similar. The rate of stent thrombosis was very low and comparable between the two stents (3 [0.1%] vs. 1 [0.1%], p=0.657). In multivariate analysis, chronic renal failure (adjusted HR 3.615, 95% CI 2.440-5.354, p&lt;0.001) and off label indication (adjusted HR 1.782, 95% CI 1.169-2.718, p=0.007) were the strongest predictors of target lesion failure. Conclusion: In this robust real world registry with unrestricted use of EES and ZES-R, both stents showed comparable safety and efficacy at 3-year follow-up. Overall incidences of target lesion failure and definite stent thrombosis, including very late stent thrombosis, were low, even in the patients with off label indications, suggesting excellent long term safety and sustained efficacy of both types of second generation drug-eluting stents.
Concomitant radiotherapy in melanoma brain metastases using the propensity score matching within the French cohort, MelBase
Authors: C. Allayous, B. Oriano, S. Dalle, L. Mortier, M.-T. Leccia, B. Guillot, G. Jeudy, C. Dutriaux, J.-P. Lacour, P. Saiag, F. Brunet-Possenti, J. De Quatrebarbes, P.-E. Stoebner, D. Legoupil, M. Beylot-Barry, T. Lesimple, F. Aubin, A. Ballon, R. Porcher, C. Lebbe
Journal: Annals of Oncology (2018)
Doctors need to improve their conversations with dying patients, says RCP
Authors: Adrian O’Dowd
Journal: BMJ (2018)

Doctors need to speak to patients with terminal illnesses in a timelier way and handle conversations with greater compassion and confidence, says a report from the Royal College of Physicians.1

The report, which examined why clinicians find it difficult to talk to patients about death, found that some doctors thought that death could be perceived as a failure and that modern medicine was expected to cure all ailments. However, evidence from patients and carers indicated that many people wanted to talk about death and that planning helped them feel more empowered about their care and decision making. …
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Authors: Désirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, Philip Mease, Atul Deodhar, Walter P Maksymowych, Filip Van den Bosch, Joachim Sieper, Tetsuya Tomita, Robert Landewé, Fangyi Zhao, Eswar Krishnan, David H. Adams, Beth Pangallo, Hilde Carlier, Melvin Churchill, Kathleen Flint, Geoffrey Gladstein, Maria Greenwald, Mary Howell, Akgun Ince, Jeffrey Kaine, Daksha Mehta, Eric Peters, Roel Querubin, John Reveille, Richard Roseff, Roger Diegel, Christine Thai, Louis Bessette, Frederic Morin, Proton Rahman, Aaron Alejandro Barrera Rodriguez, Fidencio Cons-Molina, Sergio Duran Barragan, Cassandra Skinner, Cesar Pacheco Tena, Cesar Ramos Remus, Juan Cruz Rizo Rodriguez, Seung-Jae Hong, Yeon-Ah Lee, Ji Hyeon Ju, Seong Wook Kang, Tae-Hwan Kim, Chang Keun Lee, Eun Bong Lee, Sang Heon Lee, Min-Chan Park, Kichul Shin, Sang-Hoon Lee, Hung-An Chen, Ying-Chou Chen, Song-Chou Hsieh, Joung-Liang Lan, Zdenek Dvorak, Radka Moravcova, Martina Malcova, Yoshinori Taniguchi, Mitsumasa Kishimoto, Kurisu Tada, Hiroaki Dobashi, Kentaro Inui, Yukitaka Ueki, Yoshifuji Matsumoto, Yoshinobu Koyama, Kazuhiro Hatta, Tatsuya Atsumi, Hitoshi Goto, Kiyoshi Matsui, Yuya Takakubo, Gunther Neeck, Denis Poddubnyy, Andrea Rubbert-Roth, Malgorzata Szymanska, Tomasz Blicharski, Anna Dudek, Artur Racewicz, Rafal Wojciechowski, Marleen van de Sande, Ed Griep, Mike Nurmohamed, Galina Matsievskaya, Evgeniya Shmidt, Marina Stanislav, Sergey Yakushin, Olga Ershova, Andrey Rebrov, Tibor Balazs, Regina Cseuz, Edit Drescher, Gyula Poor
Journal: The Lancet (2018)
Imaging Characteristics of a Bladder Wall Paraganglioma
Authors: Andrew John Bosserman, Dong Dai, Yang Lu
Journal: Clinical Nuclear Medicine (2018)

A 65-year-old man with a history of hypertension and nephrolithiasis presented with flank pain. Urographic CT demonstrated a 1.7-cm nodule arising from the bladder wall. The patient was referred for cystourethroscopy. During the procedure, the patient became hypertensive while under general anesthesia. No biopsy or resection was performed. To work up for possible bladder paraganglioma, a I-MIBG scan was ordered, and the patient was referred to endocrinology. On SPECT/CT images, the bladder nodule demonstrates marked uptake of MIBG radiotracer, confirming the diagnosis of a genitourinary paraganglioma arising from the bladder wall.
GW29-e0403 A Novel Cost-Effective Non-Invasive Imaging Criteria For Detection Of Hypertrophic Cardiomyopathy In Elite Athletes
Authors: Diana Foo Hui Ping, Lam Kai Huat, Adam Bin Bujang, Andrew Kilung, Sally Suriani Ahip, Ong Tiong Kiam, Alan Fong Yean Yip
Journal: Journal of the American College of Cardiology (2018)
Activity of BIBW 2992, an oral irreversible EGFR/HER2 dual kinase inhibitor, in combination with weekly paclitaxel in non-small cell lung cancer
Authors: Flora Stavridi, Rebecca Kristeleit, Martin Forster, Joo-Ern Ang, Sarah Rudman, Martina Uttenreuther-Fischer, Karine Pemberton, Mehdi Shahidi, Johann De Bono, James Spicer
Journal: Journal of Thoracic Oncology (2009)
Second Commentary: On the proper treatment of connectionism by Paul Smolensky (1988) - Neuromachismo Rekindled
Authors: Walter J Freeman
Journal: Behavioral and Brain Sciences (1989)

Author(s): Freeman, Walter J, III | Abstract: Paul Smolensky's marvelous neologisitc epithet neuromacho should not be allowed to drift into oblivion. Hence I come forth under the banner of neuromachismo to challenge his assertion that chaotic dynamics is relevant to smell in animals but not yet to speech in humans. Is there such a gulf between olfactive lagomorphs and talking people? What is the difference between a rabbit expressing its love of carrots by rhythmic cheing and sniffing and Prokoviev expressing his love for three oranges in a suite of tones? On the phylogenetic scale these are virtual twins, much as Smolensky's theory and that of Skarda and myself (1985, 1987) are so alike that we can usefully correspond.
Outcomes of primary and secondary breast diffuse large B-cell lymphoma in rituximab-era
Authors: Noriko Nishimura, Anna Nishihara, Norihito Inoue, Shoko Marshall, Hirofumi Yamauchi, Yoshiharu Kusano, Yuko Mishima, Masahiro Yokoyama, Kiyohiko Hatake, Yasuhito Terui
Journal: Annals of Oncology (2018)
Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors: Takeshi Terashima, Tatsuya Yamashita, Tadashi Toyama, Kuniaki Arai, Kazunori Kawaguchi, Kazuya Kitamura, Taro Yamashita, Yoshio Sakai, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko
Journal: Liver Cancer (2018)

Time to progression (TTP) is widely used as the endpoint in early-phase trials of advanced hepatocellular carcinoma (HCC). However, the relevance of using TTP as a surrogate marker for overall survival (OS) in pivotal trials remains uncertain. The PubMed database and ASCO Meeting Library were searched for reports of randomized controlled trials that investigated patients with advanced HCC, included data for both OS and TTP, and were launched between 2009 and 2016. The correlation between hazard ratios (HRs) for TTP and OS was determined using weighted linear regression. Correlations between median OS and TTP, and between median OS and postprogression survival (PPS), defined as the period obtained by subtracting the median TTP from the median OS, were also evaluated. The database search yielded 24 trials with 50 arms. Overall, TTP HR correlated with OS HR (R = 0.73); however, the coefficient in the regression equation was 0.48. The correlation between median OS and median TTP was not so strong (R = 0.50), whereas the correlation between median OS and median PPS was strong (R = 0.78). In advanced HCC, the OS HR can be predicted from the TTP HR, which is useful when considering whether to proceed to a pivotal trial based on the results of early-phase trials. TTP may be a better endpoint than OS for evaluating a novel agent in a pivotal trial, because an improvement in antitumor effect cannot fully reflect an improvement in OS due to the strong impact of PPS on OS.
Abstract 17866: Prognostic Impact of the Society for Vascular Surgery (SVS) Wound, Ischemia, and Foot Infection (Wifi) Classification System and Lesion Distribution on Clinical Outcomes in Real-World Practice
Authors: Yosuke Hata, Osamu Iida, Masashi Fujita, Masaharu Masuda, Shin Okamoto, Takayuki Ishihara, Kiyonori Nanto, Takashi Kanda, Takuya Tsujimura, Shota Okuno, Yasuhiro Matsuda, Takuya Ohashi, Aki Tsuji, Hiroyuki Kawai, Hiroyuki Uematsu, Yuki Sato, Toshiaki Mano
Journal: Circulation (2017)

Background: Thanks to the recent development of dedicated devices and an accumulation of experience, endovascular therapy (EVT) is becoming an alternative first-line option for the treatment of pat...
Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis
Authors: Mari Carmen Torres-Moreno, Esther Papaseit, Marta Torrens, Magí Farré
Journal: JAMA Network Open (2018)

<h3>Importance</h3> Cannabinoids have antispastic and analgesic effects; however, their role in the treatment of multiple sclerosis (MS) symptoms is not well defined. <h3>Objective</h3> To conduct a systematic review and meta-analysis to assess the efficacy and tolerability of medicinal cannabinoids compared with placebo in the symptomatic treatment of patients with MS. <h3>Data Sources</h3> MEDLINE and the Cochrane Library Plus up to July 26, 2016. No restrictions were applied. The search was completed with information from ClinicalTrials.gov. <h3>Study Selection</h3> Randomized, double-blind, and placebo-controlled trials evaluating the effect of medicinal cannabinoids by oral or oromucosal route of administration on the symptoms of spasticity, pain, or bladder dysfunction in adult patients with MS. <h3>Data Extraction and Synthesis</h3> The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines were followed. Effect sizes were calculated as standardized mean difference (SMD) for efficacy, and rate ratio (RR) for tolerability. Within each study, those SMDs evaluating the same outcome were combined before the meta-analysis to obtain a single value per outcome and study. Pooling of the studies was performed on an intention-to-treat basis by means of random-effect meta-analysis. <h3>Main Outcomes and Measures</h3> Spasticity (on the Ashworth and Modified Ashworth scales and subjective), pain, bladder dysfunction, adverse events, and withdrawals due to adverse events. <h3>Results</h3> Seventeen selected trials including 3161 patients were analyzed. Significant findings for the efficacy of cannabinoids vs placebo were SMD = −0.25 SD (95% CI, −0.38 to −0.13 SD) for spasticity (subjective patient assessment data), −0.17 SD (95% CI, −0.31 to −0.03 SD) for pain, and −0.11 SD (95% CI, −0.22 to −0.0008 SD) for bladder dysfunction. Results favored cannabinoids. Findings for tolerability were RR = 1.72 patient-years (95% CI, 1.46-2.02 patient-years) in the total adverse events analysis and 2.95 patient-years (95% CI, 2.14-4.07 patient-years) in withdrawals due to adverse events. Results described a higher risk for cannabinoids. The serious adverse events meta-analysis showed no statistical significance. <h3>Conclusions and Relevance</h3> The results suggest a limited efficacy of cannabinoids for the treatment of spasticity, pain, and bladder dysfunction in patients with MS. Therapy using these drugs can be considered as safe. <h3>Trial Registration</h3> PROSPERO Identifier:CRD42014015391
Plasma Lipidomic Profiling and Risk of Type 2 Diabetes in the PREDIMED Trial
Authors: Cristina Razquin, Estefanía Toledo, Clary B. Clish, Miguel Ruiz-Canela, Courtney Dennis, Dolores Corella, Christopher Papandreou, Emilio Ros, Ramon Estruch, Marta Guasch-Ferré, Enrique Gómez-Gracia, Montserrat Fitó, Edward Yu, José Lapetra, Dong Wang, Dora Romaguera, Liming Liang, Angel Alonso-Gómez, Amy Deik, Mónica Bullo, Lluis Serra-Majem, Jordi Salas-Salvadó, Frank B. Hu, Miguel A. Martínez-González
Journal: Diabetes Care (2018)

Specific lipid molecular changes leading to type 2 diabetes (T2D) are largely unknown. We assessed lipidome factors associated with future occurrence of T2D in a population at high cardiovascular risk.We conducted a case-cohort study nested within the PREDIMED trial, with 250 incident T2D cases diagnosed during 3.8 years of median follow-up, and a random sample of 692 participants (639 noncases and 53 overlapping cases) without T2D at baseline. We repeatedly measured 207 plasma known lipid metabolites at baseline and after 1 year of follow-up. We built combined factors of lipid species using principal component analysis and assessed the association between these lipid factors (or their 1-year changes) and T2D incidence.Baseline lysophosphatidylcholines and lysophosphatidylethanolamines (lysophospholipids [LPs]), phosphatidylcholine-plasmalogens (PC-PLs), sphingomyelins (SMs), and cholesterol esters (CEs) were inversely associated with risk of T2D (multivariable-adjusted P for linear trend ≤0.001 for all). Baseline triacylglycerols (TAGs), diacylglycerols (DAGs), and phosphatidylethanolamines (PEs) were positively associated with T2D risk (multivariable-adjusted P for linear trend <0.001 for all). One-year changes in these lipids showed associations in similar directions but were not significant after adjustment for baseline levels. TAGs with odd-chain fatty acids showed inverse associations with T2D after adjusting for total TAGs.Two plasma lipid profiles made up of different lipid classes were found to be associated with T2D in participants at high cardiovascular risk. A profile including LPs, PC-PLs, SMs, and CEs was associated with lower T2D risk. Another profile composed of TAGs, DAGs, and PEs was associated with higher T2D risk.
Population effectiveness of opportunistic chlamydia testing in primary care in Australia: a cluster-randomised controlled trial
Authors: Jane S Hocking, Meredith Temple-Smith, Rebecca Guy, Basil Donovan, Sabine Braat, Matthew Law, Jane Gunn, David Regan, Alaina Vaisey, Liliana Bulfone, John Kaldor, Christopher K Fairley, Nicola Low
Journal: The Lancet (2018)
Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G
Authors: Y. Kito, T. Yamada, T. Matsumoto, H. Yasui, K. Murata, A. Makiyama, H. Hara, E. Baba, K. Nishio, K. Yoshimura, S. Hironaka, K. Muro, K. Yamazaki
Journal: Annals of Oncology (2018)
Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity
Authors: Hui-Ming Chen, William van der Touw, Yuan Shuo Wang, Kyeongah Kang, Sunny Mai, Jilu Zhang, Dayanira Alsina-Beauchamp, James A. Duty, Sathish Kumar Mungamuri, Bin Zhang, Thomas Moran, Richard Flavell, Stuart Aaronson, Hong-Ming Hu, Hisashi Arase, Suresh Ramanathan, Raja Flores, Ping-Ying Pan, Shu-Hsia Chen
Journal: Journal of Clinical Investigation (2018)

Tumor-associated myeloid cells maintain immunosuppressive microenvironments within tumors. Identification of myeloid-specific receptors to modulate tumor-associated macrophage and myeloid-derived suppressor cell (MDSC) functions remains challenging. The leukocyte immunoglobulin-like receptor B (LILRB) family members are negative regulators of myeloid cell activation. We investigated how LILRB targeting could modulate tumor-associated myeloid cell function. LILRB2 antagonism inhibited receptor-mediated activation of SHP1/2 and enhanced proinflammatory responses. LILRB2 antagonism also inhibited AKT and STAT6 activation in the presence of M-CSF and IL-4. Transcriptome analysis revealed that LILRB2 antagonism altered genes involved in cell cytoskeleton remodeling, lipid/cholesterol metabolism, and endosomal sorting pathways, as well as changed differentiation gene networks associated with inflammatory myeloid cells as opposed to their alternatively activated phenotype. LILRB2 blockade effectively suppressed granulocytic MDSC and Treg infiltration and significantly promoted in vivo antitumor effects of T cell immune checkpoint inhibitors. Furthermore, LILRB2 blockade polarized tumor-infiltrating myeloid cells from non–small cell lung carcinoma tumor tissues toward an inflammatory phenotype. Our studies suggest that LILRB2 can potentially act as a myeloid immune checkpoint by reprogramming tumor-associated myeloid cells and provoking antitumor immunity.
Cicatrizing Blepharoconjunctivitis Occurring During Dupilumab Treatment and a Proposed Algorithm for Its Management
Authors: Russell M. Levine, Ian W. Tattersall, Paul A. Gaudio, Brett A. King
Journal: JAMA Dermatology (2018)

This case report describes a patient who developed cicatrizing blepharoconjunctivitis while undergoing dupilumab treatment and proposes an algorithm for the management of dupilumab-associated conjunctivitis.
The Giving Body
Authors: Adam Philip Stern
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting
Authors: Sorin J. Brener, Patrick W. Serruys, Marie-Claude Morice, Roxana Mehran, Arie Pieter Kappetein, Joseph F. Sabik, Yangbo Liu, Ovidiu Dressler, Ori Ben-Yehuda, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2018)
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
Authors: Kerry A. Rogers, Ying Huang, Amy S. Ruppert, Farrukh T. Awan, Nyla A. Heerema, Corinne Hoffman, Gerard Lozanski, Kami J. Maddocks, Mollie E. Moran, Mark A. Reid, Margaret Lucas, Jennifer A. Woyach, W. Thomas Whitlow, Jeffrey A. Jones, John C. Byrd
Journal: Blood (2018)
Abstract 14586: Total Scar Burden Predicts Cardiac Resynchronization Therapy (CRT) Response Beyond Left Bundle Branch Block (LBBB) and QRS Duration (QRSd) and Regardless of the Type of Cardiomyopathy (CM)
Authors: Serge C Harb, Nisarat Chareonsri, Zoran Popovic, Aman Wahaj, Niraj Varma, Scott Flamm, Deborah Kwon
Journal: Circulation (2015)

Introduction: Prior studies have demonstrated that up to 30% of patients do not benefit from CRT and that response may be affected by the extent and location of myocardial scar. We sought to determine the predictive value of the scar burden on CRT response after controlling for the type of cardiomyopathy (Ischemic=ICM vs. Non-Ischemic=NICM), the presence of LBBB and QRSd. Methods: We reviewed 71 pts (49% NICM, age 71 +/- 11, 34% women) who underwent cardiac MRI (CMR) pre-CRT. Total and lateral wall % scar were measured and pre-CRT ECG features (LBBB and QRSd) were noted. The change in EF on echo &gt;6 months post-CRT was calculated and a positive response was defined as a ≥10% increase in left ventricular ejection fraction (EF). The relationship between LBBB, QRSd, total and lateral scar % and change in EF were investigated using Pearson (r) correlation. Hierarchical multiple regression was used to assess the ability of total and lateral scar burden to predict CRT response after controlling for the type of CM, the presence of LBBB and QRSd. Results: Mean EF pre-CRT was 23.6%+/-8 and correlated significantly with EF by CMR (mean =24.4 +/-10; r = 0.5, p&lt;0.01). LBBB was present in 52% of pts and mean QRSd was 152ms. A positive response to CRT was noted in 52% of pts. The change in EF correlated significantly with the presence of LBBB (0.31; p=0.01), QRSd (0.27; p=0.03); total scar % (-0.39; p&lt;0.01) and lateral scar % (-0.28;p=0.02). After controlling for the type of CM, and presence of LBBB and QRSd, total scar % was still significantly predictive of the response to CRT [R squared change (tot scar) = 0.06, F change (1,63) = 16, p=0.01] - see table 1. With lateral scar, the same analysis was not significant [R squared change (lat scar)=0.04, F change (1,62)=3.5 p=0.06] Conclusion: Assessment of total scar burden provides incremental predictive value to CRT response after controlling for the type of CM (ICM vs. NICM), the presence of LBBB and QRSd.
Publisher Correction: Neuromodulation of lumbosacral spinal networks enables independent stepping after complete paraplegia
Authors: Megan L. Gill, Peter J. Grahn, Jonathan S. Calvert, Margaux B. Linde, Igor A. Lavrov, Jeffrey A. Strommen, Lisa A. Beck, Dimitry G. Sayenko, Meegan G. Van Straaten, Dina I. Drubach, Daniel D. Veith, Andrew R. Thoreson, Cesar Lopez, Yury P. Gerasimenko, V. Reggie Edgerton, Kendall H. Lee, Kristin D. Zhao
Journal: Nature Medicine (2018)